Compare Iron Mountain Inc (IRM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs ResMed Inc. — how do they compare? Iron Mountain Inc trades at $114.1 (market cap $34.46B), while ResMed Inc. trades at $229.93 (market cap $31.89B). The key difference: Iron Mountain Inc and ResMed Inc. are close in size by market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and ResMed Inc. for 51 Days on average.
| IRM | RMD | |
|---|---|---|
Market Cap | $34.46B | $31.89B |
Volume | 1,379,608 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $277.88 |
52-Week Low | $78.86 | $182.82 |
Typical Hold Time | 80 Days | 51 Days |
Enterprise Value | $53.87B | $31.24B |
Dividend Yield | 2.99% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong institutional interest. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent news highlights expansion in data centers and digital partnerships, including a 300MW pipeline and AI collaborations.
The outlook is supported by analyst consensus with a $142.75 price target (66.7% buy ratings), but high debt levels and elevated P/E of 82.09 pose risks. Earnings growth from digital initiatives is the key catalyst, while leverage and margin pressure require monitoring for sustained shareholder value.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
